Radiopharm Theranostics Raises $4.1M in Direct Offering, Eyes Additional $8.9M
Event summary
- Radiopharm Theranostics secures $4.1M via registered direct offering of 1.28M ADSs at $3.16 per share.
- Concurrent private placement includes warrants for up to 1.28M additional ADSs, exercisable at $3.79 each by July 31, 2029.
- Australian Placement and Share Purchase Plan could raise up to A$12.7M ($8.9M), subject to shareholder approval.
- Proceeds will fund RAD101 registrational study, clinical milestones, partnering initiatives, and working capital.
The big picture
Radiopharm Theranostics' $4.1M direct offering and potential A$12.7M in additional funding underscore its push to advance oncology radiopharmaceuticals amid high unmet medical need. The concurrent capital raise reflects both urgency to fund clinical trials and strategic flexibility in a competitive biotech financing landscape.
What we're watching
- Clinical Milestones
- How the $4.1M infusion will accelerate RAD101 registrational study and other therapeutic programs.
- Shareholder Dynamics
- Whether September shareholder approvals will clear path for additional A$12.7M in funding.
- Strategic Partnering
- The pace at which Radiopharm advances partnering initiatives with proceeds from the offering.
Related topics